This double-blind, randomised trial (n=32) will compare the effects of methylphenidate- versus MDMA-assisted therapy (120mg) for mood and anxiety symptoms in advanced-stage cancer patients.
Participants will receive a single session of either MDMA (120mg oral dose with an optional 60mg supplemental dose) or methylphenidate (20mg oral dose with an optional 10mg supplemental dose). The therapy sessions will last for 8 hours in a comfortable non-clinical environment and will be guided by specific therapy manuals. Both groups will undergo pre and post-therapy sessions, including therapeutic support sessions before and after dosing.
The primary outcome measure is the change from the baseline score of the Montgomery Asberg Depression Scale, assessed 28 days post-dosing. Secondary outcomes include changes in anxiety symptoms, palliative outcomes, mystical experiences, and adverse events.
The trial is being conducted at the University of Otago, New Zealand, and is funded by various sources, including individual donors and the Multidisciplinary Association for Psychedelic Studies (MAPS).
The principal investigator is Prof Paul Glue, who can be contacted for further information. Data sharing will be available upon request, subject to approval by the principal investigator, and includes individual participant data, study protocol, statistical analysis plan, informed consent form, clinical study report, ethical approval, and analytic code.
Please find the study protocol here.
Trial Details
Trial Number
Sponsors & Collaborators
University of OtagoThe University of Otago (specifically the Dunedin School of Medicine) is associated with psychedelic research but doesn't yet have a full profile.